Clinical Trial Update: A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma [Phase 1, Phase 2]

View source ↗

Summary

This update describes the completion of a Phase 1/2 study evaluating galunisertib (LY2157299) in combination with temozolomide-based radiochemotherapy for newly…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Glioma

Drugs mentioned

• Galunisertib (galunisertib)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Glioma | Phase 1, Phase 2 | Status: COMPLETED